Abstract
The spread of COVID-19 across the world continues as efforts are being made from multi-dimension to curtail its spread and provide treatment. The COVID-19 triggered partial and full lockdown across the globe in an effort to prevent its spread. COVID-19 causes serious fatalities with United States of America recording over 3,000 deaths within 24 hours, the highest in the world for a single day. In this paper, we propose a framework integrated with machine learning to curtail the spread of COVID-19 in smart cities. A novel mathematical model is created to show the spread of the COVID-19 in smart cities. The proposed solution framework can generate, capture, store and analyze data using machine learning algorithms to detect, prevent the spread of COVID-19, forecast next epidemic, effective contact tracing, diagnose cases, monitor COVID-19 patient, COVID-19 vaccine development, track potential COVID-19 patients, aid in COVID-19 drug discovery and provide better understanding of the virus in smart cities. The study outlined case studies on the application of machine learning to help in the fight against COVID-19 in hospitals in smart cities across the world. The framework can provide a guide for real world execution in smart cities. The proposed framework has the potential for helping national healthcare systems in curtailing the COVID-19 pandemic in smart cities.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
The study does not require clinical trial
Funding Statement
No funding for this manuscript
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
NA
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
No data is associated with this manuscript
